CNS-5161 hydrochloride is used as a novel and selective noncompetitive antagonist of the NMDA subset of glutamate receptors; it exhibits potent inhibitory activity at the NMDA ion channel; it protects against the necrotic effects of exogenous N-methyl-D-aspartate in neonatal rat NMDA excitotoxicity models; it shows 91% inhibition of audiogenic seizures in DBA/2 mice; and it demonstrates neuroprotective effects following hypoxic/ischemic brain injury in neonatal rats.